Chemotherapy-Induced Peripheral Neurotoxicity assessment: a critical revision of the currently available tools
- PMID: 20045310
- DOI: 10.1016/j.ejca.2009.12.008
Chemotherapy-Induced Peripheral Neurotoxicity assessment: a critical revision of the currently available tools
Abstract
Chemotherapy-Induced Peripheral Neurotoxicity (CIPN) is a frequent, potentially severe and dose-limiting side-effect of cancer treatment. Despite its clinical relevance that limits the use of several antineoplastic agents and even the future development of new anticancer drugs, several crucial aspects of CIPN remain unsolved, one of which is how to assess its occurrence and severity in the most effective and reliable way. CIPN severity is generally assessed using Common Toxicity Criteria (CTC) scales, although it is well known that significant inter-observer disagreement exists using these scales. Moreover, most CTC scores mix impairment, disability and quality of life measures, which could lead to misinterpretation of the results and unpredictable under- or overestimation of the effect. This uncertainty may lead to different interpretations of the results of the same clinical trials by clinicians and also by regulatory agencies. The use of other types of scale based on clinical and instrumental examinations, or the use of self-administered questionnaires for patients, has not yet really improved the accuracy of CIPN assessment, although some of these tools are promising and deserve to be further validated. As a result, there is a general recognition that CIPN has still not been properly assessed and that improvements should be made. In this review, the available data regarding the different tools used to assess CIPN will be revised and their features will be critically examined, with a special focus on their reliability and reproducibility across examiners and, when available, through direct comparison.
Copyright (c) 2009 Elsevier Ltd. All rights reserved.
Similar articles
-
The Total Neuropathy Score as an assessment tool for grading the course of chemotherapy-induced peripheral neurotoxicity: comparison with the National Cancer Institute-Common Toxicity Scale.J Peripher Nerv Syst. 2007 Sep;12(3):210-5. doi: 10.1111/j.1529-8027.2007.00141.x. J Peripher Nerv Syst. 2007. PMID: 17868248
-
Chemotherapy-induced peripheral neurotoxicity can be misdiagnosed by the National Cancer Institute Common Toxicity scale.J Peripher Nerv Syst. 2011 Sep;16(3):228-36. doi: 10.1111/j.1529-8027.2011.00351.x. J Peripher Nerv Syst. 2011. PMID: 22003937
-
Multi-center assessment of the Total Neuropathy Score for chemotherapy-induced peripheral neurotoxicity.J Peripher Nerv Syst. 2006 Jun;11(2):135-41. doi: 10.1111/j.1085-9489.2006.00078.x. J Peripher Nerv Syst. 2006. PMID: 16787511
-
Chemotherapy-induced peripheral neurotoxicity (CIPN): an update.Crit Rev Oncol Hematol. 2012 Apr;82(1):51-77. doi: 10.1016/j.critrevonc.2011.04.012. Epub 2011 Sep 10. Crit Rev Oncol Hematol. 2012. PMID: 21908200 Review.
-
The total neuropathy score: a tool for measuring chemotherapy-induced peripheral neuropathy.Oncol Nurs Forum. 2008 Jan;35(1):96-102. doi: 10.1188/08.ONF.96-102. Oncol Nurs Forum. 2008. PMID: 18192158 Review.
Cited by
-
Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial.JAMA. 2013 Apr 3;309(13):1359-67. doi: 10.1001/jama.2013.2813. JAMA. 2013. PMID: 23549581 Free PMC article. Clinical Trial.
-
Therapeutic Effects of Phytochemicals and Medicinal Herbs on Chemotherapy-Induced Peripheral Neuropathy.Molecules. 2016 Sep 20;21(9):1252. doi: 10.3390/molecules21091252. Molecules. 2016. PMID: 27657026 Free PMC article. Review.
-
Quantitative assessment of chemotherapy-induced peripheral neurotoxicity using a point-of-care nerve conduction device.Cancer Sci. 2016 Oct;107(10):1453-1457. doi: 10.1111/cas.13010. Epub 2016 Sep 2. Cancer Sci. 2016. PMID: 27412083 Free PMC article.
-
A Pilot, Phase II, Randomized, Open-Label Clinical Trial Comparing the Neurotoxicity of Three Dose Regimens of Nab-Paclitaxel to That of Solvent-Based Paclitaxel as the First-Line Treatment for Patients with Human Epidermal Growth Factor Receptor Type 2-Negative Metastatic Breast Cancer.Oncologist. 2019 Nov;24(11):e1024-e1033. doi: 10.1634/theoncologist.2017-0664. Epub 2019 Apr 25. Oncologist. 2019. PMID: 31023863 Free PMC article. Clinical Trial.
-
CYP3A genetic variation and taxane-induced peripheral neuropathy: a systematic review, meta-analysis, and candidate gene study.Front Pharmacol. 2023 Jul 4;14:1178421. doi: 10.3389/fphar.2023.1178421. eCollection 2023. Front Pharmacol. 2023. PMID: 37469869 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials